Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Yoon Soo Chae

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2762-3286; OpenAlex author ID A5104245652. Sources: OpenAlex.

Their work

Papers
14 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
38
Papers, trials and grants by year

2024: 3 papers · 2025: 6 papers · 2026: 5 papers

Papers 14

  1. International multicenter validation of an 18F-fluorodeoxyglucose positron emission tomography/computed tomography maximum standardized uptake value 4.0 thresh… Co-author DOI 10.1016/j.surg.2026.110503↗
  2. Distinct clinicopathologic features and efficacy of adjuvant therapy in intraductal papillary mucinous carcinoma compared with conventional pancreatic ductal a… Co-author DOI 10.1016/j.suronc.2026.102368↗
  3. ASO Visual Abstract: Evaluating Tumor Regression and Survival Outcomes in Pancreatic Ductal Adenocarcinoma After Neoadjuvant Treatment According to CAP Grading… Co-author DOI 10.1245/s10434-025-18349-8↗
  4. Correction: Evaluating Tumor Regression and Survival Outcomes in Pancreatic Ductal Adenocarcinoma After Neoadjuvant Treatment according to CAP Grading System: … Co-author DOI 10.1245/s10434-026-20624-1↗
  5. Comparison of postoperative survival after neoadjuvant treatment versus upfront surgery in resected pancreatic ductal adenocarcinoma: a propensity score matchi… Co-author DOI 10.4174/astr.2026.111.2.93↗
  6. Long-term oncologic outcomes of robot-assisted pancreaticoduodenectomy versus open pancreaticoduodenectomy for pancreatic cancer. Co-author DOI 10.1007/s00464-025-11833-y↗
  7. Efficacy of Neoadjuvant Radiotherapy After Chemotherapy and the Optimal Interval from Radiotherapy to Surgery for Borderline Resectable and Resectable Pancreat… First author DOI 10.1245/s10434-024-16743-2↗
  8. Changing Clinical Meaning of Resection Margin Status According to the Treatment Paradigm and the Potential Role of Perioperative Radiotherapy for Patients with… Co-author DOI 10.1245/s10434-025-17389-4↗
  9. Evaluating Tumor Regression and Survival Outcomes in Pancreatic Ductal Adenocarcinoma After Neoadjuvant Treatment according to CAP Grading System: Clinical Use… Co-author DOI 10.1245/s10434-025-18123-w↗
  10. Impact of Nutritional Changes on the Prognosis in Pancreatic Cancer Patients Underwent Curative Surgery After Neoadjuvant Chemotherapy. Co-author DOI 10.3390/nu17040647↗
  11. Evaluation of feasibility and clinical outcomes of robot-assisted pancreaticoduodenectomy after neoadjuvant treatment for patients with advanced pancreatic duc… Co-author DOI 10.4174/astr.2025.109.2.61↗
  12. Re-evaluation of risk and oncological outcomes of resection of veins and arteries in the resection of pancreatic cancer. First author DOI 10.1002/jhbp.12048↗
  13. Clinical outcomes of preservation versus resection of portal/superior mesenteric vein during pancreaticoduodenectomy in pancreatic cancer patients who respond … Co-author DOI 10.1097/js9.0000000000002034↗
  14. Comparing clinical and genomic features based on the tumor location in patients with resected pancreatic cancer. Co-author DOI 10.1186/s12885-024-12795-5↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wooil Kwon · 14 shared papers, 2024–2026 · strength 3.40
  2. Hye‐Sol Jung · 13 shared papers, 2024–2026 · strength 3.20
  3. Jin‐Young Jang · 13 shared papers, 2024–2026 · strength 3.20
  4. Won‐Gun Yun · 12 shared papers, 2024–2026 · strength 2.92
  5. Joon Seong Park · 8 shared papers, 2024–2026 · strength 2.03
  6. Go‐Won Choi · 7 shared papers, 2025–2026 · strength 1.82
  7. Younsoo Seo · 7 shared papers, 2025–2026 · strength 1.82
  8. Youngmin Han · 3 shared papers, 2025–2026 · strength 0.76
  9. Young‐Jae Cho · 3 shared papers, 2024–2025 · strength 0.67
  10. Mirang Lee · 3 shared papers, 2024 · strength 0.64
  11. Seulah Park · 2 shared papers, 2024–2025 · strength 0.45
  12. Yoo‐Seok Yoon · 2 shared papers, 2025–2026 · strength 0.44
  13. Wonjun Jang · 1 shared paper, 2026 · strength 0.28
  14. Ha Eun Kim · 1 shared paper, 2025 · strength 0.26
  15. Chang-Sup Lim · 1 shared paper, 2025 · strength 0.25
  16. Eui Kyu Chie · 1 shared paper, 2025 · strength 0.25
  17. Daechan Park · 1 shared paper, 2024 · strength 0.20
  18. Isamu Makino · 1 shared paper, 2026 · strength 0.19
  19. Atsushi Tomioka · 1 shared paper, 2026 · strength 0.19
  20. Teiichi Sugiura · 1 shared paper, 2026 · strength 0.19
  21. Shintaro Yagi · 1 shared paper, 2026 · strength 0.19
  22. Tetsuya Idichi · 1 shared paper, 2026 · strength 0.19
  23. Kousei Ishigami · 1 shared paper, 2026 · strength 0.19
  24. Hongbeom Kim · 1 shared paper, 2026 · strength 0.19
  25. Hyung Il Seo · 1 shared paper, 2026 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.